Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Prostate ; 72(8): 846-55, 2012 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-21919028

RESUMEN

BACKGROUND: In order for tumors to grow and proliferate, they must avoid recognition by immune cells and subsequent death by apoptosis. Granzyme B (GrB), a protease located in natural killer cells, initiates apoptosis in target cells. Inhibition of GrB by PI-9, its natural inhibitor, can prevent apoptosis. Here we investigate whether PI-9 protects prostate cancer cells from apoptosis. METHODS: The expression of PI-9 was quantified by qPCR in several prostate cancer cell lines, and GrB activity was tested in each cell line. PI-9 was overexpressed in LNCaP cells, which lack endogenous PI-9. Apoptosis was induced by natural killer cells in LNCaP cells that either contained or lacked PI-9, and the percent cell death was quantified. Lastly, PI-9 levels were examined by qPCR and immunohistochemistry in prostate tumor tissue. RESULTS: Prostate cancer cell lines that expressed PI-9 could inhibit GrB. Overexpression of PI-9 protected LNCaP cells from natural killer cell-mediated apoptosis. Examination of the levels of PI-9 in tissue from prostate tumors showed that PI-9 could be upregulated in low grade tumors and stochastically dysregulated in high grade tumors. Additionally, PI-9 was found consistently in high grade prostatic intraepithelial neoplasia and atrophic lesions. CONCLUSIONS: These results indicate that overexpression of PI-9 can protect prostate cancer cells from apoptosis, and this effect may occur in human prostate tumors. These findings imply that early prostatic inflammation may trigger this increase in PI-9. This suggests that PI-9 upregulation is needed early in tumor progression, before additional protective mechanisms are in place.


Asunto(s)
Adenocarcinoma/metabolismo , Granzimas/antagonistas & inhibidores , Neoplasias de la Próstata/metabolismo , Serpinas/metabolismo , Adenocarcinoma/patología , Apoptosis/fisiología , Línea Celular Tumoral , Progresión de la Enfermedad , Humanos , Masculino , Neoplasias de la Próstata/patología , Regulación hacia Arriba
2.
J Biol Chem ; 282(38): 27865-74, 2007 Sep 21.
Artículo en Inglés | MEDLINE | ID: mdl-17620340

RESUMEN

The extended substrate specificity of granzyme B (GrB) was used to identify substrates among the chaperone superfamily. This approach identified Hsp90 and Bag1-L as novel GrB substrates, and an additional GrB cleavage site was identified in the Hsc70/Hsp70-Interacting Protein, Hip. Hsp90, Bag1L, and Hip were validated as GrB substrates in vitro, and mutational analysis confirmed the additional cleavage site in Hip. Because the role of Hip in apoptosis is unknown, its proteolysis by GrB was used as a basis to test whether it has anti-apoptotic activity. Previous work on Hip was limited to in vitro characterization; therefore, it was important to demonstrate Hip cleavage in a physiological context and to show its relevance to natural killer (NK) cell-mediated death. Hip is cleaved at both GrB cleavage sites during NK-mediated cell death in a caspase-independent manner, and its cleavage is due solely to GrB and not other granule components. Furthermore, Hip is not cleaved upon stimulation of the Fas receptor in the Jurkat T-cell line, suggesting that Hip is a substrate unique to GrB. RNA interference-mediated reduction of Hip within the K562 cell line rendered the cells more susceptible to NK cell-mediated lysis, indicating that proteolysis by GrB of Hip contributes to death induction. The small effect of RNA interference-mediated Hip deficiency on cytotoxicity is in agreement with the inherent redundancy of NK cell-mediated cell death. The identification of additional members of the chaperone superfamily as GrB substrates and the validation of Hip as an anti-apoptotic protein contribute to understanding the interplay between stress response and apoptosis.


Asunto(s)
Factores de Coagulación Sanguínea/fisiología , Granzimas/química , Apoptosis , Factores de Coagulación Sanguínea/química , Fragmentación del ADN , Humanos , Células Jurkat , Células K562 , Células Asesinas Naturales/metabolismo , Chaperonas Moleculares/metabolismo , Estrés Oxidativo , Plásmidos/metabolismo , Conformación Proteica , Estructura Terciaria de Proteína , ARN Interferente Pequeño/metabolismo , Proteínas de Unión al ARN , Proteínas Ribosómicas , Factores de Tiempo
3.
J Biol Chem ; 281(38): 28326-35, 2006 Sep 22.
Artículo en Inglés | MEDLINE | ID: mdl-16798735

RESUMEN

Granzyme B is critical to the ability of natural killer cells and cytotoxic T lymphocytes to induce efficient cell death of virally infected or tumor cell targets. Although granzyme B can cleave and activate caspases to induce apoptosis, granzyme B can also cause caspase-independent cell death. Thirteen prospective granzyme B substrates were identified from a cDNA expression-cleavage screen, including Hsp70, Notch1, fibroblast growth factor receptor-1 (FGFR1), poly-A-binding protein, cAbl, heterogeneous nuclear ribonucleoprotein H', Br140, and intersectin-1. Validation revealed that Notch1 is a substrate of both granzyme B and caspases, whereas FGFR1 is a caspase-independent substrate of granzyme B. Proteolysis of FGFR1 in prostate cancer cells has functionally relevant consequences that indicate its cleavage may be advantageous for granzyme B to kill prostate cancer cells. Therefore, granzyme B not only activates pro-death functions within a target, but also has a previously unidentified role in inactivating pro-growth signals to cause cell death.


Asunto(s)
Apoptosis , Proteínas HSP70 de Choque Térmico/metabolismo , Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/metabolismo , Receptor Notch1/metabolismo , Serina Endopeptidasas/farmacología , Secuencia de Aminoácidos , Caspasas/fisiología , Línea Celular Tumoral , Proliferación Celular , Supervivencia Celular , Biblioteca de Genes , Granzimas , Humanos , Masculino , Datos de Secuencia Molecular , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA